MedPath

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Phase 3
Completed
Conditions
Type 1 Diabetes
Diabetes
Interventions
Registration Number
NCT05463744
Lead Sponsor
Eli Lilly and Company
Brief Summary

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
692
Inclusion Criteria
  • Have a clinical diagnosis of type 1 diabetes for at least 1 year prior to screening
  • Have received treatment with basal-bolus insulin analog multiple daily injection therapy according to the local product label for at least 90 days prior to screening
  • Have an HbA1c value of 7.0% to 10.0%, inclusive, as determined by the central laboratory at screening.
  • Have a body mass index of ≤35 kilogram/square meter (kg/m²)
Exclusion Criteria
  • Have a diagnosis of type 2 diabetes, latent autoimmune diabetes, or specific types of diabetes other than type 1 diabetes
  • Have a history of more than 1 episode of severe hypoglycemia, within the 6 months prior to screening.
  • Have a history of more than 1 episode of diabetic ketoacidosis or hyperosmolar state or coma requiring hospitalization within the 6 months prior to screening.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Insulin Efsitora AlfaInsulin Efsitora AlfaParticipants will receive insulin efsitora alfa by subcutaneously (SC)
Insulin DegludecInsulin DegludecParticipants will receive insulin degludec SC
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Hemoglobin A1c (HbA1c)Baseline, Week 26
Secondary Outcome Measures
NameTimeMethod
Time in Glucose RangeWeek 49 to Week 52

Time in Glucose Range between 70 and 180 mg/dL (3.9 and 10.0 mmol/L) inclusive, measured by continuous glucose monitoring (CGM) 4 weeks prior to week 52.

Change from Baseline in Body WeightBaseline, Week 26 and Baseline, Week 52
Nocturnal Hypoglycemia Event RateBaseline to Week 52

The event rate of participant-reported clinically significant nocturnal hypoglycemia (\<54 mg/dL or severe) measured during treatment phase up to week 52.

Change from Baseline in Fasting GlucoseBaseline, Week 26 and Baseline, Week 52

Change from baseline in fasting glucose measured by self-monitoring of blood glucose (SMBG).

Change from Baseline in HbA1cBaseline, Week 52
Basal Insulin DoseWeek 26 and Week 52
Bolus Insulin DoseWeek 26 and Week 52
Total Insulin DoseWeek 26 and Week 52
Rate of Composite Level 2 and 3 Hypoglycemia EventsBaseline to Week 52
Glucose VariabilityWeek 23 to Week 26 and Week 49 to Week 52

Glucose variability measured by CGM 4 weeks prior to week 26 and week 52.

Time in Hyperglycemia RangeWeek 23 to Week 26 and Week 49 to Week 52

Time in hyperglycemia range defined as glucose \>180 mg/dL, measured by CGM 4 weeks prior to week 26 and week 52.

Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ)Baseline, Week 26 and Baseline, Week 52

DTSQ consists of 8 items and assesses the overall treatment satisfaction and perceived frequency of hyperglycemia and hypoglycemia.

Time in Hypoglycemia RangeWeek 23 to Week 26 and Week 49 to Week 52

Time in hypoglycemia range defined as time in hypoglycemia with glucose \<54 mg/dL, measured by CGM 4 weeks prior to week 26 and week 52.

Change from Baseline in Short Form-36 Version 2 (SF-36 v2) Acute Form Domain ScoresBaseline, Week 26 and Baseline, Week 52

SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality.

Trial Locations

Locations (82)

Palm Research Center Tenaya

🇺🇸

Las Vegas, Nevada, United States

Biopharma Informatic, LLC

🇺🇸

Houston, Texas, United States

Amir A Hassan, MD, PA

🇺🇸

Houston, Texas, United States

Sansum Diabetes Research Institute

🇺🇸

Santa Barbara, California, United States

East-West Medical Research Institute

🇺🇸

Honolulu, Hawaii, United States

Valley Research

🇺🇸

Fresno, California, United States

Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care

🇺🇸

Fort Lauderdale, Florida, United States

SUNY Upstate Medical University

🇺🇸

Syracuse, New York, United States

Instituto Médico Especializado (IME)

🇦🇷

Buenos Aires, Argentina

Cotton O'Neil Clinical Research Center

🇺🇸

Topeka, Kansas, United States

Catalina Research Institute, LLC

🇺🇸

Montclair, California, United States

Southern Endocrinology Associates

🇺🇸

Mesquite, Texas, United States

NYU Langone Hospital - Long Island

🇺🇸

Mineola, New York, United States

Rainier Clinical Research Center

🇺🇸

Renton, Washington, United States

Iowa Diabetes and Endocrinology Research Center

🇺🇸

West Des Moines, Iowa, United States

Northeast Research Institute (NERI)

🇺🇸

Fleming Island, Florida, United States

John Muir Physician Network Research Center

🇺🇸

Concord, California, United States

University Clinical Investigators, Inc.

🇺🇸

Tustin, California, United States

Hanson Clinical Research Center

🇺🇸

Port Charlotte, Florida, United States

North Texas Endocrine Center

🇺🇸

Dallas, Texas, United States

NYC Research

🇺🇸

New York, New York, United States

Endocrine and Metabolic Consultants

🇺🇸

Rockville, Maryland, United States

East Coast Institute for Research at The Jones Center

🇺🇸

Macon, Georgia, United States

Rocky Mountain Clinical Research

🇺🇸

Idaho Falls, Idaho, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Texas Diabetes & Endocrinology, P.A.

🇺🇸

Round Rock, Texas, United States

Consultorio de Investigación Clínica EMO SRL

🇦🇷

Ciudad Autonoma de Buenos Aire, Buenos Air, Argentina

Dallas Diabetes Research Center

🇺🇸

Dallas, Texas, United States

Research Institute of Dallas

🇺🇸

Dallas, Texas, United States

Suncoast Clinical Research, Inc.

🇺🇸

New Port Richey, Florida, United States

Manda Memorial Hospital

🇯🇵

Sapporo, Hokkaido, Japan

Centro de Investigaciones Metabólicas (CINME)

🇦🇷

Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina

CIAD Moron

🇦🇷

Moron, Buenos Air, Argentina

Investigaciones Medicas Imoba Srl

🇦🇷

Balvanera, Ciudad Autónoma De Buenos Aire, Argentina

Abe Clinic

🇯🇵

Oita, Japan

Hachioji Diabetes Clinic

🇯🇵

Hachioji-shi, Tokyo, Japan

NBR Polska

🇵🇱

Warszawa, Mazowiecki, Poland

Centro Medico Privado CEMAIC

🇦🇷

Capital, Córdoba, Argentina

NZOZ Medica

🇵🇱

Lublin, Lubelskie, Poland

Advanced Clinical Research, LLC

🇵🇷

Bayamon, Puerto Rico

CIPADI - Centro Integral de Prevencion y Atencion en Diabetes

🇦🇷

Godoy Cruz, Mendoza, Argentina

Shimizu Clinic Fusa

🇯🇵

Saitama-shi, Saitama, Japan

Jinnouchi Hospital

🇯🇵

Kumamoto, Japan

Takatsuki Red Cross Hospital

🇯🇵

Takatsuki, Osaka, Japan

Centro Diabetológico Dr. Waitman

🇦🇷

Córdoba, Argentina

Tosaki Clinic for Diabetes and Endocrinology

🇯🇵

Nagoya-shi, Aichi, Japan

Private Practice - Dr. Janusz Gumprecht

🇵🇱

Zabrze, ÅšlÄ…skie, Poland

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

🇵🇱

Krakow, Małopolskie, Poland

Centrum Medyczne "Diabetika"

🇵🇱

Radom, Mazowieckie, Poland

Chung Shan Medical University Hospital

🇨🇳

Taichung City, Taichung, Taiwan

Takai Internal Medicine Clinic

🇯🇵

Kamakura-shi, Kanagawa, Japan

Gabinety TERPA

🇵🇱

Lublin, Lubelskie, Poland

Centralny Szpital Kliniczny MSWiA w Warszawie

🇵🇱

Warszawa, Mazowieckie, Poland

Centrum Badan Klinicznych PI-House sp. z o.o.

🇵🇱

Gdansk, Pomorskie, Poland

Endocrinologist Metabolic Clinic & Research Institute

🇵🇷

San Juan, Puerto Rico

Tatratrial s.r.o.

🇸🇰

Rožňava, Košický Kraj, Slovakia

Funkystuff

🇸🇰

Nove Zamky, Nitriansky Kraj, Slovakia

ENDIAMED s.r.o

🇸🇰

Dolny Kubin, Žilinský Kraj, Slovakia

Changhua Christian Hospital

🇨🇳

Changhua, Taiwan

SN ZOZ Lege Artis Poradnia Diabetologiczna

🇵🇱

Bialystok, Podlaskie, Poland

Centro de Salud e Investigaciones Médicas

🇦🇷

Santa Rosa, La Pampa, Argentina

Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L

🇦🇷

San Miguel de Tucuman, Tucumán, Argentina

Centro Medico Privado de Reumatologia

🇦🇷

San Miguel De Tucumán, Tucumán, Argentina

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

The Institute for Adult Disease, Asahi Life Foundation

🇯🇵

Chuo-ku, Tokyo, Japan

NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny

🇵🇱

Bialystok, Podlaskie, Poland

Chi Mei Medical Center

🇨🇳

Tainan City, Tainan, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung City, Taichung, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei City, Taipei, Taiwan

MinamiAkatsukaClinic

🇯🇵

Mito, Ibaraki, Japan

Nakakinen clinic

🇯🇵

Naka, Ibaraki, Japan

Noritake Clinic

🇯🇵

Ushiku, Ibaraki, Japan

Clinic Masae Minami

🇯🇵

Fukuoka, Japan

Heiwadai Hospital

🇯🇵

Miyazaki, Japan

Mautalen Salud e Investigación

🇦🇷

Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina

Centro Medico Privado San Vicente Diabetes

🇦🇷

Cordoba, Córdoba, Argentina

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

Clinvest Research LLC

🇺🇸

Springfield, Missouri, United States

MedStar Health Research Institute (MedStar Physician Based Research Network)

🇺🇸

Hyattsville, Maryland, United States

Research Foundation of SUNY - University of Buffalo

🇺🇸

Buffalo, New York, United States

Palm Research Center Sunset

🇺🇸

Las Vegas, Nevada, United States

CEDIC

🇦🇷

Caba, Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath